Tazemetostat, an inhibitor of the histone-lysine N-methyltransferase enhancer of zeste homolog 2 (EZH2), demonstrated efficacy in a phase II trial including patients with advanced epithelioid sarcoma with INI1/SMARCB1 loss: an objective response rate (ORR) was reached in 15% of patients, with a median progression-free survival (PFS) of 5.5 months (95% CI 3.4–5.9) and median OS (overall survival) of 19.0 months (11.0—not estimable) [11]. The gene discussed is SMARCB1; the disease is epithelioid sarcoma.